{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T10:33:32Z","timestamp":1722162812966},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Amgen Europe GmbH"},{"name":"Fonds Europ\u00e9en de D\u00e9veloppement \u00c9conomique et R\u00e9gional","award":["CIBERONC CB16\/12\/00284"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00284"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s41669-018-0098-8","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T09:43:10Z","timestamp":1539596590000},"page":"229-235","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain"],"prefix":"10.1007","volume":"3","author":[{"given":"Blanca","family":"Boluda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Regadera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Senent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Vicente","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Solves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Reitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Gea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"issue":"11","key":"98_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10552-015-0657-6","volume":"26","author":"AJ Katz","year":"2015","unstructured":"Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control CCC. 2015;26(11):1627\u201342.","journal-title":"Cancer Causes Control CCC"},{"issue":"12","key":"98_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N Gokbuget","year":"2016","unstructured":"Gokbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u201333.","journal-title":"Haematologica"},{"key":"98_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12885-015-1745-4","volume":"15","author":"D Saltman","year":"2015","unstructured":"Saltman D, Barlev A, Seshagiri D, Katsoulis I, Lin V, Barber B. Management and treatment of relapsed or refractory Ph(\u2212) B-precursor ALL: a web-based, double-blind survey of EU clinicians. BMC Cancer. 2015;15:771.","journal-title":"BMC Cancer."},{"issue":"Suppl 5","key":"98_CR4","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v69\u201382.","journal-title":"Ann Oncol"},{"issue":"5","key":"98_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/bjh.14107","volume":"174","author":"JM Bergua","year":"2016","unstructured":"Bergua JM, Montesinos P, Martinez-Cuadron D, Fernandez-Abellan P, Serrano J, Sayas MJ, et al. A prognostic model for survival after salvage treatment with FLAG-Ida\u2009\u00b1\u2009gemtuzumab-ozogamicine in adult patients with refractory\/relapsed acute myeloid leukaemia. Br J Haematol. 2016;174(5):700\u201310.","journal-title":"Br J Haematol"},{"issue":"4","key":"98_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.farma.2011.05.002","volume":"36","author":"L Dominguez Senin","year":"2012","unstructured":"Dominguez Senin L, Rodriguez Rodriguez JN, Garrido Martinez MT, Sanchez Argaiz M, Martin Chacon E. Effectiveness and safety of the FLAG-IDA regimen in acute refractory or recurrent leukaemia. Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2012;36(4):261\u20137.","journal-title":"Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria."},{"issue":"12","key":"98_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s00277-005-1090-9","volume":"84","author":"G Specchia","year":"2005","unstructured":"Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory\/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005;84(12):792\u20135.","journal-title":"Ann Hematol"},{"key":"98_CR8","unstructured":"Oblikue Consulting. eSalud\u2014Informaci\u00f3n econ\u00f3mica del sector sanitario. http:\/\/esalud.oblikue.com\/ . Accessed 14 Mar 2018."},{"key":"98_CR9","unstructured":"Ministry of Health and Social Services and Equity. Instituto de Informaci\u00f3n Sanitaria (2018). Registro de altas\u2014CMBD 2016. http:\/\/pestadistico.inteligenciadegestion.msssi.es\/publicoSNS\/comun\/DefaultPublico.aspx . Accessed 14 Mar 2018."},{"issue":"7","key":"98_CR10","doi-asserted-by":"publisher","first-page":"A443","DOI":"10.1016\/j.jval.2015.09.1094","volume":"18","author":"L Pagano","year":"2015","unstructured":"Pagano L, Oberti M, Esposito B, Reitan J, Barlev A, Barber BL, et al. Retrospective chart review of hospitalisations during chemotherapy for adult patients with Ph-negative B-precursor relapsed or refractory (R\/R) acute lymphoblastic leukaemia (ALL) in Italy. Value Health J Int Soc Pharmacoecon Outcomes Res. 2015;18(7):A443.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"11","key":"98_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1080\/13696998.2016.1192549","volume":"19","author":"H Dombret","year":"2016","unstructured":"Dombret H, Thomas X, Chevallier P, Nivot E, Reitan J, Barber B, et al. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. J Med Econ. 2016;19(11):1034\u20139.","journal-title":"J Med Econ"},{"issue":"7","key":"98_CR12","doi-asserted-by":"publisher","first-page":"A443","DOI":"10.1016\/j.jval.2015.09.1096","volume":"18","author":"K Kreuzer","year":"2015","unstructured":"Kreuzer K, Stuhlmann R, Lebioda A, Reitan J, Barber BL, Barlev A. Hospitalisations among adult patients with Ph-negative B-precursor relapsed or refractory (R\/R) acute lymphoblastic leukaemia (ALL) receiving chemotherapy in Germany: a retrospective chart review. Value Health J Int Soc Pharmacoecon Outcomes Res. 2015;18(7):A443.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"8","key":"98_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0145-2126(02)00003-6","volume":"26","author":"J Rubia de la","year":"2002","unstructured":"de la Rubia J, Regadera A, Martin G, Cervera J, Sanz G, Martinez J, et al. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res. 2002;26(8):725\u201330.","journal-title":"Leuk Res"},{"issue":"7","key":"98_CR14","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1185\/03007995.2016.1164677","volume":"32","author":"A Barlev","year":"2016","unstructured":"Barlev A, Lin VW, Song X. Burden of hospitalization in relapsed acute lymphoblastic leukemia. Curr Med Res Opin. 2016;32(7):1209\u201312.","journal-title":"Curr Med Res Opin"},{"issue":"22","key":"98_CR15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood.V128.22.222.222","volume":"128","author":"MS Topp","year":"2016","unstructured":"Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Schuh AC, et al. Health-related quality of life (HRQoL) of blinatumomab versus standard of care (SOC) chemotherapy in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). Blood. 2016;128(22):222.","journal-title":"Blood"},{"issue":"9","key":"98_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"8","key":"98_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"key":"98_CR18","unstructured":"Red Espa\u00f1ola de Costes Hospitalarios (RECH). https:\/\/rechosp.org . Accessed 27 Feb 2018."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-018-0098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-018-0098-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-018-0098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T02:46:27Z","timestamp":1605235587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-018-0098-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1007\/s41669-018-0098-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"15 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study and medical writing support for this article were sponsored by Amgen (Europe) GmbH. This work was partially financed with Fonds Europ\u00e9en de D\u00e9veloppement \u00c9conomique et R\u00e9gional (FEDER) funds (CIBERONC CB16\/12\/00284).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BB has no disclosures. RRV has no disclosures. DMC has no disclosures. IL has no disclosures. JS has no disclosures. AR has no disclosures. AS has no disclosures. LS has no disclosures. JVC has no disclosures. PS has no disclosures. JR is an employee of RJM Group; RJM received funding from Amgen to conduct this study. SG is an employee of Amgen and holds stock in Amgen Inc. MAS has no disclosures. PM has received remuneration from Amgen for a speaker bureau.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the Research Ethics Board of the hospital, in accordance with the principles of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}